Chronic obstructive pulmonary disease phenotypes, biomarkers, and prognostic indicators

Allergy and Asthma Proceedings

Volumn 37, Issue 6, 2016, Pages 432-438

  Brightling, Christopher E ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENRALIZUMAB; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; GLUCOCORTICOID; LONG ACTING DRUG; MACROLIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE MARKER; EMPHYSEMA; GENETIC SCREENING; HUMAN; MICROORGANISM; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRACTICE GUIDELINE; PROGNOSIS; RESPIRATORY TRACT INFLAMMATION; SYMPTOM; TREATMENT RESPONSE; AIRWAY REMODELING; COMPLICATION; INFECTION; INFLAMMATION; MICROBIOLOGY; PATHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VIROLOGY;

AIRWAY REMODELING; BIOMARKERS; EMPHYSEMA; HUMANS; INFECTION; INFLAMMATION; PHENOTYPE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84995617405     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2016.37.3996     Document Type: Article

References (61)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2015. Available online at http://www.goldcopd.org/; accessed June 20, 2016.
2. National Institute for Clinical Excellence (NICE) COPD Guideline 2010. Available online at https://www.nice.org.uk/guidance/CG101; accessed June 20, 2016.
3. May SM, and Li JT. Burden of chronic obstructive pulmonary disease: Healthcare costs and beyond. Allergy Asthma Proc 36:4-10, 2015.
4. Donaldson GC, Seemungal TA, Bhowmik A, and Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57: 847-852, 2002.
5. Parker CM, Voduc N, Aaron SD, et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 26:420-428, 2005.
6. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am J Respir Crit Care Med 182:598-604, 2010.
7. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645-2653, 2004.
8. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364:709-721, 2004.
9. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163:1304-1309, 2001.
10. Maestrelli P, Saetta M, Mapp CE, and Fabbri LM. Remodeling in response to infection and injury. Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164(pt. 2):S76-S80, 2001.
11. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 365:1567-1575, 2011.
12. Hartley RA, Barker BL, Newby C, et al. Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: A single-center study. J Allergy Clin Immunol 137:1413-1422.e12, 2016.
13. Bafadhel M, Umar I, Gupta S, et al. The role of CT scanning in multidimensional phenotyping of COPD. Chest 140:634-642, 2011.
14. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 364:897-906, 2011.
15. Parr DG, Stoel BC, Stolk J, et al. Influence of calibration on densitometric studies of emphysema progression using computed tomography. Am J Respir Crit Care Med 170:883-890, 2004.
16. Parr DG, Stoel BC, Stolk J, and Stockley RA. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med 170: 1172-1178, 2004.
17. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 158:1277-1285, 1998.
18. Simpson JL, Scott R, Boyle MJ, and Gison PG. Inflammatory subtypes in asthma: Assessment and identification using induced sputum. Respirology 11:54-61, 2006.
19. Brightling CE. Clinical applications of induced sputum. Chest 129:1344-1348, 2006.
20. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 356: 1480-1485, 2000.
21. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 60:193-198, 2005.
22. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 158:1511-1517, 1998.
23. Siva R, Green RH, Brightling CE, et al. Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial. Eur Respir J 29:906-913, 2007.
24. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: Prevalence and clinical characteristics. Eur Respir J 44:1697-1700, 2014.
25. Amelink M, de Nijs SB, de Groot JC, et al. Three phenotypes of adult-onset asthma. Allergy 68:674-680, 2013.
26. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 178: 218-224, 2008.
27. Newby C, Heaney LG, Menzies-Gow A, et al. Statistical cluster analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical outcomes and phenotype stability. PloS One 9:e102987, 2014.
28. Wardlaw AJ, Silverman M, Siva R, et al. Multi-dimensional phenotyping: Towards a new taxonomy for airway disease. Clin Exp Allergy 35:1254-1262, 2005.
29. Braman SS. The chronic obstructive pulmonary disease-asthma overlap syndrome. Allergy Asthma Proc 36:11-18, 2015.
30. Ghebre MA, Bafadhel M, Desai D, et al. Biological clustering supports both "Dutch" and "British" hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 135:63-72, 2015.
31. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 184:662-671, 2011.
32. Saetta M, Di Stefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 150(pt. 1):1646-1652, 1994.
33. Zhu J, Qiu YS, Majumdar S, et al. Exacerbations of bronchitis: Bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 164:109-116, 2001.
34. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174:867-874, 2006.
35. Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177:269-278, 2008.
36. Quint JK, Donaldson GC, Goldring JJ, et al. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest 137:812-822, 2010.
37. Stockley RA, O'Brien C, Pye A, and Hill Sl. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117:1638-1645, 2000.
38. Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 152(pt. 1):1316-1320, 1995.
39. Banerjee D, Khair OA, and Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 23:685-691, 2004.
40. Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173:991-998, 2006.
41. Wilkinson TM, Patel IS, Wilks M, et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:1090-1095, 2003.
42. Barker BL, Haldar K, Patel H, et al. Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations. Chest 147:46-55, 2015.
43. Singh R, Mackay AJ, Patel AR, et al. Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res 15:114, 2014.
44. Wang Z, Bafadhel M, Haldar K, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J 47:1082-1092, 2016.
45. DjukanovićR, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 145:669-674, 1992.
46. Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3:435-442, 2015.
47. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: A biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192:523-525, 2015.
48. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371:1285-1294, 2014.
49. Brightling CE, Pavord ID, and Bafadhel M. Inhaled glucocorticoids and COPD exacerbations. N Engl J Med 372:93, 2015.
50. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: A post-hoc analysis of the WISDOM trial. Lancet Respir Med 4:390-398, 2016.
51. Russell R, and Brightling C. Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma. Expert Rev Respir Med 10:607-617, 2016.
52. Ghazi A, Trikha A, and Calhoun WJ. Benralizumab-A humanized mAb to IL-5Rα with enhanced antibody-dependent cellmediated cytotoxicity-A novel approach for the treatment of asthma. Expert Opin Biol Ther 12:113-118, 2012.
53. Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: A randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2:891-901, 2014.
54. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365:689-698, 2011.
55. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax 68:322-329, 2013.
56. Walters JA, Gibson PG, Wood-Baker R, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev (1):CD001288, 2009.
57. Puhan MA, Vollenweider D, Latshang T, et al. Exacerbations of chronic obstructive pulmonary disease: When are antibiotics indicated? A systematic review. Respir Res 8:30, 2007.
58. Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalised exacerbations of COPD. Chest 150:320-328, 2016.
59. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of COPD: A randomized placebo controlled trial. Am J Respir Crit Care Med 186:48-55, 2012.
60. Bafadhel M, Davies L, Calverley PM, et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis. Eur Respir J 44:789-791, 2014.
61. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin- based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. JAMA 302:1059-1066, 2009.